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Abstract
A preventive HIV-1 vaccine should induce HIV-1–specific broadly neutralizing antibodies 
(bnAbs). However, bnAbs generally require high levels of somatic hypermutation (SHM) to 
acquire breadth, and current vaccine strategies have not been successful in inducing bnAbs. 
Because bnAbs directed against a glycosylated site adjacent to the third variable loop (V3) of the 
HIV-1 envelope protein require limited SHM, the V3-glycan epitope is an attractive vaccine target. 
By studying the cooperation among multiple V3-glycan B cell lineages and their coevolution with 
autologous virus throughout 5 years of infection, we identify key events in the ontogeny of a V3-
glycan bnAb. Two autologous neutralizing antibody lineages selected for virus escape mutations 
and consequently allowed initiation and affinity maturation of a V3-glycan bnAb lineage. The 
nucleotide substitution required to initiate the bnAb lineage occurred at a low-probability site for 
activation-induced cytidine deaminase activity. Cooperation of B cell lineages and an improbable 
mutation critical for bnAb activity defined the necessary events leading to breadth in this V3-
glycan bnAb lineage. These findings may, in part, explain why initiation of V3-glycan bnAbs is 
rare, and suggest an immunization strategy for inducing similar V3-glycan bnAbs.
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INTRODUCTION
A vaccine to prevent HIV-1 infection should include immunogens that can induce broadly 
neutralizing antibodies (bnAbs) (1, 2). Of the five major targets for bnAbs, the glycan-rich 
apex of the HIV-1 envelope (Env) trimer and the base of the third variable loop (V3) are 
distinguished by the potency of antibodies directed against them (3–8). Although these 
antibodies have less breadth than those directed against the CD4-binding site (CD4bs) or the 
gp41 membrane-proximal external region (MPER), one current goal of vaccine development 
is to elicit them in combination with other bnAb specificities to achieve broad coverage of 
transmitted/founder (TF) viruses to prevent HIV-1 integration upon exposure (1, 2).
Mapping the coevolution of virus and antibody lineages over time informs vaccine design by 
defining the succession of HIV-1 Env variants that evolve in vivo during the course of bnAb 
development (9–11). Antibody lineages with overlapping specificities can influence each 
other’s affinity maturation by selecting for synergistic or antagonistic escape mutations: an 
example of such “cooperating” lineages is provided by two CD4bs-directed bnAbs that we 
characterized previously (11, 12). Thus, cooperating antibody lineages and their viral escape 
mutants allow identification of the specific Envs, among the diverse repertoire of mutated 
Envs that develop within the autologous quasi-species in the infected individual, that 
stimulate bnAb development and that we wish to mimic in a vaccine.
Here, we describe the coevolution of an HIV-1 Env quasi-species and a memory B cell 
lineage of gp120 V3-glycan–directed bnAbs in an acutely infected individual followed over 
time as broadly neutralizing plasma activity developed. To follow virus evolution, we 
sequenced ~1200 HIV-1 env genes sampled over a 5-year period; to follow the antibody 
response, we identified natural heavy- and light-chain pairs of six antibodies from a bnAb 
lineage, designated DH270, and augmented this lineage by next-generation sequencing 
(NGS). Structural studies defined the position of the DH270 Fab on gp140 Env. We also 
found two B cell lineages (DH272 and DH475) with neutralization patterns that likely 
selected for observed viral escape variants, which, in turn, stimulated the DH270 lineage to 
potent neutralization breadth. We found a mutation in the DH270 heavy chain that occurred 
early in affinity maturation at a disfavored activation-induced cytidine deaminase (AID) site 
and that was necessary for bnAb lineage initiation. This improbable mutation can explain the 
long period of antigenic stimulation needed for initial expansion of the bnAb B cell lineage 
in this individual.
RESULTS
Three N332 V3-glycan–dependent antibody lineages
We studied an African male from Malawi (CH848) followed from the time of infection up to 
5 years after transmission. He was infected with a clade C virus, developed plasma 
neutralization breadth 3.5 years after transmission, and did not receive antiretroviral therapy 
during this time as per country treatment guidelines. Reduced plasma neutralization of 
N332A Env–mutated HIV-1 pseudoviruses and plasma neutralization fingerprinting 
demonstrated the presence of N332-sensitive bnAbs (table S1) (13). To identify these 
antibodies, we studied memory B cells from weeks 205, 232, and 234 after infection using 
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memory B cell cultures (14) and antigen-specific sorting (15, 16) and found three N332-
sensitive lineages, designated DH270, DH272, and DH475. Their genealogy was augmented 
by the NGS of memory B cell complementary DNA from seven time points from week 11 to 
week 240 after transmission.
DH270 antibodies were recovered from memory B cells at all three sampling times (weeks 
205, 232, and 234), and expansion of the clone did not occur until week 186 (Fig. 1A and 
table S2). Clonal expansion was concurrent with the development of plasma neutralization 
breadth (tableS3), and members oftheDH270 lineage also displayed neutralization breadth 
(Fig. 1B and data set S1). The most potent DH270 lineage bnAb (DH270.6) was isolated 
using a fluorophore-labeled Man9-V3 glycopeptidethatisamimicoftheV3-glycan bnAb 
epitope (16), which comprises a discontinuous 30–amino acid residue peptide segment 
within gp120 V3 and is representative of the PGT128-bound minimal epitope described by 
Pejchal et al. (17). The synthetic Man9-V3 glycopeptide includes high-mannose glycan 
residues (Man9) each at N301 and N332 and was synthesized using a chemical process 
similar to that described previously (18, 19). The V3-glycan bnAb PGT128 affinity for the 
Man9-V3 glycopeptide was similar to that of PGT128 for the BG505 SOSIP trimer, and 
Man9-V3 glycopeptide was therefore an effective affinity bait for the isolation of V3-glycan 
bnAbs (16). The lineage derived from a VH1–2*02 rearrangement that produced a CDRH3 
[complementarity-determiningregion(CDR)H3]of20–amino acid residues paired with a light 
chain encoded by Vλ2–23 (fig. S1). Neutralization assays and competition with theV3-
glycan bnAbs PGT125 and PGT128 confirmed dependence of lineage on the potential N-
linked glycosylation (PNG) site at N332 (fig. S2).
The DH475 mAb was recovered from memory B cells at week 232 after transmission by 
antigen-specific sorting using the fluorophore-labeled Man9-V3 glycopeptide (16). The 
earliest DH475 lineage VH(D)JH rearrangements were identified with the use of NGS at 
week 64 after transmission (fig. S3A and table S2). Its heavy chain came from VH3–23*01 
[VH (variable gene of immunoglobulin heavy chain) mutation frequency, 10.1%] paired with 
a Vλ4–69*02 light chain (fig. S3B).
The DH272 mAb came from cultured memory B cells obtained at week 205 after 
transmission. DH272 lineage VH(D)JH rearrangements were detected as early as 19 weeks 
after transmission by NGS (fig. S3A and table S2). The DH272 heavy chain used VH1–
2*02, as did DH270, but it paired with a Vκ2–30 light chain. Its CDR H3 was 17 amino 
acids long; VH mutation was 14.9%. DH272, an immunoglobulin A (IgA) isotype, had a six-
nucleotide deletion in FR H3 (fig. S3B).
For both DH272 and DH475 lineages, binding to CH848 TF Env gp120 depended on the 
N332 PNG site (fig. S3C). DH272 binding also depended on the N301 PNG site (fig. S3C). 
Neither lineage had neutralization breadth (fig. S3D).
Evolution of the CH848 virus quasi-species
We sequenced 1223 HIV-1 3′ half single genomes from the virus in plasma collected at 26 
time points over 246 weeks. Analysis of sequences from the earliest plasma sample 
indicated that CH848 had been infected with a single, subtype clade C founder virus, ~ 17 
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(confidence interval, 14 to 19) days before screening (figs. S4 and S5). By week 51 after 
infection, 91% of the sequences had acquired an identical 10-residue deletion in variable 
loop 1 (V1), a region that includes the PGT128-proximal residues 133 to 135 and 141 (figs. 
S6 and S7). Further changes accrued during the ensuing 4 years, including additional 
insertions and deletions in V1, mutations in the 324GDIR327 motif within the V3 loop, 
deletion or shifting of N-linked glycosylation sites at positions 301 and 322, and mutations 
at PGT128-proximal positions in V1, V3, and C4; however, none of these escape variants 
went to fixation during the 4.5 years of follow-up (figs. S6 to S9).
Simultaneous with the first detection of DH270 lineage antibodies at week 186, four 
autologous virus clades emerged, which defined distinct immunological resistance profiles 
of the CH848 autologous quasi-species (fig. S6). The first clade included viruses that shifted 
the PNG site at N332 to N334 (fig. S6, open circles), and despite the fact that this mutation 
was associated with complete resistance to the DH270 lineage bnAbs, this clade was 
detected only transiently and at a relatively low frequency (7 to 33% per sample), suggesting 
a balance where immune escape was countered by a cost in virological fitness. Conversely, 
viruses in the other three clades retained N332 and persisted throughout the 5 years of 
sampling. Viruses in the second clade resisted DH270 lineage neutralization and comprised 
gp120 Envs that were not bound by the DH270 antibodies (fig. S6, triangles, and data set 
S2). The third and fourth clades defined autologous viruses whose gp120 Env was bound by 
DH270 lineage antibodies but that were either only weakly neutralized by the most mature 
members of the DH270 lineage (fig. S6, “X,” and data set S2) or completely neutralization-
resistant (fig. S6, “+,” and data set S2), respectively. Persistence of four divergent clades in 
the CH848 Env, each with distinctive immunological resistance phenotypes, suggests that 
multiple distinctive immune escape routes were explored and selected, allowing continuing 
Env escape mutations to accrue in distinct frameworks and exposing the antibody to Env 
diversity that may have been necessary to acquire neutralization breadth.
Ontogeny of DH270 lineage and acquisition of neutralization breadth
As with other V3-glycan bnAbs, viral neutralization clade specificity and intraclade breadth 
of DH270 depended primarily on the frequency of the N332 glycosylation site within the 
relevant clade (Fig. 2A). Only 1 of the 62 pseudoviruses tested that lacked the PNG site at 
N332, the B clade virus 5768.04, was sensitive to DH270.5 and DH270.6 (data set S1). 
Across the full panel of M group HIV-1 virus isolates used in neutralization assays, the loss 
of the PNG N332 sites accounted for 70% of the observed neutralization resistance. The 
circulating recombinant form CRF01 rarely has this glycosylation site [3% of sequences in 
the Los Alamos database and 4% (1 of 23) in our test panel], and the DH270 lineage 
antibodies did not neutralize CRF01 strains (Fig. 2A). As a consequence of the N332 PNG 
site requirement of V3-glycan bnAbs to neutralize, in vitro estimation of neutralizing 
breadth was affected simply by the fraction of CRF01 viruses included in the panel. Other 
V3-glycan bnAbs (10-1074, PGT121, and PGT128) shared this N332 glycan dependency, 
but PGT121 and PGT128 were not as restrictive (data set S1) (5, 6, 8). Antibody 10-1074 
was similar to DH270.6, in that it more strictly required the N332 PNG site, and its 
neutralization potency correlated with that of DH270.6 (Pearson’s r = 0.63, P = 8.0 × 10−13) 
(8).
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Heterologous breadth and potency of the DH270 lineage antibodies increased with the 
accumulation of VH mutations, and although DH270.UCA did not neutralize heterologous 
HIV-1, five amino acid substitutions in DH270.IA4 (four in the heavy chain and one in the 
light chain) were sufficient to initiate the bnAb lineage and confer heterologous 
neutralization (Fig. 2, B and C, and data set S3).
The capacity of the early DH270 lineage members to neutralize heterologous viruses 
correlated with the presence of short V1 loops (Fig. 2D). As the lineage evolved, it gained 
capacity to neutralize viruses with longer V1 loops, although with reduced potency (Fig. 2D 
and fig. S10, A to C). Neutralization of the same virus panel by the V3-glycan bnAbs 
10-1074, PGT121, and PGT128 followed the same inverse correlation between potency and 
V1 length (fig. S10, D to F).
Mutations in the DH270 antibody lineage that initiated heterologous neutralization
The likelihood of AID-generated somatic mutation in immunoglobulin genes has strong 
nucleotide sequence dependence (20, 21). Moreover, we have recently shown for CD4bs 
bnAbs that VH sites of high intrinsic mutability determine many sites of somatic 
hypermutation (11). Like the VRC01-class CD4bs bnAbs, both DH270 and DH272 used 
VH1–2*02, although unlike the CD4bs bnAbs, V3-glycan bnAbs in general can use quite 
disparate VH gene segments (3, 17, 22–25). Antibodies in both lineages have mutations at 
the same amino acid positions that correspond to sites of intrinsic mutability that we 
identified in the VH1–2*02 CD4bs bnAbs (fig. S11A) (11). In HIV-1–negative individuals, 
we identified 20 amino acids that frequently mutate from the VH1–2*02 germline sequence 
(fig. S11A). Twelve of these 20 amino acids were also frequently mutated in the DH270 
lineage antibodies, and 11 of these 12 amino acids mutated to 1 of the 2 most frequent 
amino acids mutated in non–HIV-1 VH1–2*02 sequences (identity conformity). G57R was 
the lone exception. DH272 mutated in 6 of these 12 positions, and CD4bs bnAb VRC01 
mutated in 11 of 12 positions (fig. S11A).
The presence of the canonical VH1–2*02 allele in individual CH848 was confirmed by 
genomic DNA sequencing (fig. S11B). Four nucleotide changes in the DH270.UCA 
conferred heterologous neutralization activity on the next intermediate antibody (IA4). The 
G92A and G102A nucleotide mutations in DH270.IA4 (and in DH272) occurred at 
“canonical” AID hotspots (DGYW) and encoded amino acid substitutions G31D and M34I, 
respectively (Fig. 3A). G164C (G164A for DH272) was in a “noncanonical” AID hotspot 
with a comparable level of mutability (20) and encoded the S55T (N for DH272) 
substitution (Fig. 3A). In contrast, the G169C mutation in DH270.IA4, which encoded the 
G57R amino acid mutation, occurred at a site with a very low predicted level of mutability 
(20), generated a canonical cold spot (GTC), and disrupted the overlapping AID hotspot at 
G170 within the same codon, which was instead used by DH272 and resulted in the G57V 
substitution (Fig. 3A). Thus, although both the DH270 bnAb and DH272 autologous 
neutralizing lineages had mutations at Gly57, the substitution in the DH270 lineage (G57R) 
was an improbable event, whereas the substitution (G57V) in the DH272 lineage was much 
more probable.
Bonsignori et al. Page 6
Sci Transl Med. Author manuscript; available in PMC 2017 August 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The G31D and M31I substitutions that occurred in AID hotspots became fixed in both 
lineages, and S55T eventually became prevalent also in the DH272 lineage (Fig. 3B). By 
week 111 after transmission, all DH272 lineage VH(D)JH transcripts sequenced by NGS 
harbored a mutation in the Gly57 codon, which resulted in the predominance of an encoded 
aspartic acid (Fig. 3B). In contrast, only 6 of 758 (0.8%) DH270 lineage transcripts isolated 
186 weeks after transmission had Val57 or Asp57; 48 of 758 (6.3%) retained Gly57, whereas 
over two-thirds, 514 of 758 (67.8%), had G57R (Fig. 3B).
Because the rare G169C nucleotide mutation in DH270.IA4 introduced a cold spot and 
simultaneously disrupted the overlapping AID hotspot, it had a high probability of being 
maintained once it occurred, and indeed, it was present in 523 of 758 (68%) DH270 lineage 
VH sequences identified with NGS at week 186 after transmission (Fig. 3C).
Reversion of Arg57 to Gly abrogated DH270.IA4 neutralization of autologous and 
heterologous HIV-1 isolates (Fig. 3D). A DH270.IA4 R57V mutant (with the base change 
that would have occurred had the overlapping AID hotspot been used) also greatly reduced 
DH270.IA4 neutralization, confirming that Arg57, rather than the absence of Gly57, was 
responsible for the acquired neutralizing activity (Fig. 3D). Finally, the DH270. UCA G57R 
mutant neutralized both autologous and heterologous viruses, confirming that G57R alone 
could confer neutralizing activity on the DH270 germline antibody (Fig. 3E). Thus, the 
improbable G169C mutation conferred reactivity against autologous virus and initiated 
acquisition of heterologous neutralization breadth in the DH270 lineage.
A search for an Env that might select for the critical G57R mutation in DH270. UCA or 
IA4-like antibodies yielded Env 10.17 at week 135 of infection (fig. S12, A and B), which 
derived from the only autologous virus Env that DH270.IA4 could bind. DH270.IA4 binding 
to Env 10.17 depended on the presence of Arg57, and reversion of Arg57 to Gly (R57G) was 
necessary and sufficient to abrogate binding (fig. S12A). Also, binding to Env 10.17 was 
acquired by DH270.UCA upon introduction of the G57R mutation (fig. S12B).
Autologous neutralizing antibody lineages that cooperated with DH270
Evidence for functional interaction among the three N332-dependent lineages came from the 
respective neutralization profiles against a panel of 90 autologous viruses from TF to week 
240 after transmission (Fig. 4A and data set S2). Both DH475 and DH272 neutralized 
autologous viruses isolated during the first year of infection, which were resistant to most 
DH270 lineage antibodies (only DH270. IA1 and DH270.4 neutralized weakly) (Fig. 4A). 
DH475 neutralized viruses from week 15 to week 39, and DH272 neutralized the CH848 TF 
and all viruses isolated up to week 51, when viruses that resisted DH475 and DH272 
became strongly sensitive to the more mature antibodies in the DH270 lineage (VH 
nucleotide mutation frequency, ≥5.6%) (Fig. 4A).
The identification of specific mutations implicated in the switch of virus sensitivity was 
complicated by the high levels of mutations accumulated by virus Env over time (fig. S13 
and data set S4). We identified virus signatures that defined the DH270.1 and DH272/
DH475 immunotypes and introduced four of them, in various combinations, into the DH272/
DH475-sensitive virus that was closest in sequence to the DH270.1-sensitive immunotype: a 
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10–amino acid deletion in V1 (Δ134–143); a D185N mutation in V2, which introduced an 
N-linked glycosylation site; an N413Y mutation in V4, which disrupted an N-linked 
glycosylation site; and a 2–amino acid deletion (Δ463–464) in V5.
The large V1 deletion was critical for DH270.1 neutralization, with smaller contributions 
from the other changes; the V1 deletion increased virus resistance to DH475 (3.5-fold 
increase). V1 loop– mediated resistance to DH475 neutralization increased further when 
combined with the Δ463–464 V5 deletion (5-fold increase) (Fig. 4B).
The V1 loop of the TF virus (34 residues) was longer than the average V1 length of 28 
residues (range, 11 to 64) of HIV-1 Env sequences found in the Los Alamos Sequence 
Database (26). As observed for heterologous neutralization, DH270 lineage antibodies 
acquired the ability to neutralize larger fractions of autologous viruses as maturation 
progressed by gaining activity for viruses with longer V1 loops, although at the expense of 
lower potency (fig. S14, A to C). This correlation was less clear for gp120 binding (fig. S14, 
D to F), however, suggesting that the V1 loop length dependency of V3-glycan bnAb 
neutralization has a conformational component. Thus, DH475 cooperated with the DH270 
bnAb lineage by selecting viral escape mutants sensitive to bnAb lineage members.
For DH272, the viral variants that we made did not implicate a specific cooperating escape 
mutation. The Δ134–143 (V1 deletion) mutated virus remained sensitive to DH272 
neutralization; both combinations of the V1 deletion in our panel that were resistant to 
DH272 and sensitive to DH270.1 included D185N, which also caused DH272 resistance on 
its own but did not lead to DH270.1 sensitivity (Fig. 4C). Thus, we have suggestive, but not 
definitive, evidence that DH272 also participated in selecting escape mutants for the DH270 
bnAb lineage.
Structure of DH270 lineage members
We determined crystal structures for the single-chain variable fragment of DH270.1 and the 
Fabs of DH270.UCA3, DH270.3, DH270.5, and DH270.6, as well as DH272 (table S4). 
Because of uncertainty in the inferred sequence of the germline precursor (fig. S15, A and 
B), we also determined the structure of DH270.UCA1, which has a somewhat differently 
configured CDR H3 loop (fig. S15C); reconfiguration of this loop during early affinity 
maturation could account for the observed increase with respect to the UCA in heterologous 
neutralization by several intermediates. The variable domains of the DH270 antibodies 
superposed well, indicating that affinity maturation modulated the antibody-antigen interface 
without substantially changing the antibody conformation (Fig. 5A). Mutations accumulated 
at different positions for DH270 lineage bnAbs in distinct branches (fig. S16), possibly 
accounting for their distinct neutralization properties. DH272 had a CDR H3 configured 
differently from that of DH270 lineage members and a significantly longer CDR L1 (Fig. 
5B), compatible with their distinct neutralization profiles.
We also compared the structures of DH270 lineage members with those of other N332-
dependent bnAbs. All appear to have one long CDR loop that can extend through the 
network of glycans on the surface of the gp120 subunit and contact the “shielded” protein 
surface. The lateral surfaces of the Fab variable module can then interact with the 
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reconfigured or displaced glycans to either side. PGT128 has a long CDR H2 (Fig. 5C), in 
which a six-residue insertion is critical for neutralization breadth and potency (5, 17). 
PGT124 has a shorter and differently configured CDR H2 loop, but a long CDR H3 instead 
(Fig. 5D) (27).
Structure of the DH270–HIV-1 Env complex
We determined a three-dimensional image reconstruction, from negative-stain electron 
microscopy (EM), of the DH270.1 Fab bound with a gp140 trimer (92Br SOSIP.664) (Fig. 5, 
E and F, and fig. S17). The three DH270.1 Fabs project laterally, with their axes nearly 
normal to the threefold of gp140, in a distinctly more “horizontal” orientation than seen for 
PGT124, PGT135, and PGT128 (Fig. 5, G and H, and fig. S18). This orientational 
difference is consistent with differences between DH270 and PGT124 or PGT128 in the 
lengths and configurations of their CDR loops, which required an alternative DH270 bnAb 
position when docked onto the surface of the Env trimer. We docked the BG505 SOSIP 
coordinates (28) and the Fab into the EM reconstruction and further constrained the EM 
reconstruction image by the observed effects of BG505 SOSIP mutations in the gp140 
surface image (figs. S17 and S19). Asp325 was essential for binding DH270.1 because it is a 
potential partner for Arg57 on the Fab. Mutating Asp321 led to a modest loss in affinity; 
R327A had no effect (fig. S20). These data further distinguish DH270 from PGT124 and 
PGT128. Individually mutating W101, Y105, D107, D115, Y116, or W117 in DH270.1 to 
alanine substantially reduced binding to the SOSIP trimer, as did pairwise mutation to the 
alanines of S106 and S109. The effects of these mutations illustrate the critical role of the 
CDR H3 loop in binding with HIV-1 Env (fig. S20).
DH270.UCA binding
The DH270.UCA did not bind to any of the 120 CH848 autologous gp120 Env 
glycoproteins isolated from time of infection to week 245 after infection, including the TF 
Env (Fig. 6A). DH270.UCA, as well as maturation intermediate antibodies, also did not 
recognize free glycans or cell surface membrane–expressed gp160 trimers (Fig. 6B). 
Conversely, the DH270.UCA bound to the Man9-V3 synthetic glycopeptide mimic of the 
V3-glycan bnAb gp120 epitope (fig. S21A) and also bound to the aglycone form of the same 
peptide (fig. S21B). Similarly, the early intermediate antibodies (IA4, IA3, and IA2) each 
bound to both the Man9-V3 glycopeptide and its aglycone form, and their binding was 
stronger to the aglycone V3 peptide than to the Man9-V3 glycopeptide (fig. S21B). Overall, 
binding of the DH270.UCA and early intermediate antibodies to the Man9-V3 glycopeptide 
was low (>10 μM) (fig. S21A). DH270.1 (VH nucleotide mutation frequency, 5.6%) bound 
the glycopeptide with higher affinity than did the aglycone (Kd,glycopeptide = 331 nM) (fig. 
S21, A and B), and as mutations accumulated, binding of the Man9-V3 glycopeptide also 
increased, culminating in a Kd (apparent dissociation constant) of 188 nM in the most potent 
bnAb, DH270.6, which did not bind to the aglycone V3 peptide (fig. S21, A and B). Thus, 
both the Man9-V3 glycopeptide and the aglycone V3 peptide bound to the DH270.UCA, and 
antibody binding was independent of glycans until the DH270 lineage had acquired a 
nucleotide mutation frequency of ~6%.
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DISCUSSION
We can reconstruct from the data presented here a plausible series of events during the 
development of a V3-glycan bnAb in a natural infection. The DH272 and DH475 lineages 
neutralized the autologous TF and early viruses, and the resulting escape viruses were 
neutralized by the DH270 lineage. In particular, V1 deletions were necessary for 
neutralization of all but the most mature DH270 lineage antibodies. DH475 (and possibly 
DH272) escape variants stimulated DH270 affinity maturation, including both somatic 
mutations at sites of intrinsic mutability (11) and a crucial, improbable mutation at an AID 
cold spot within CDR H2 (G57R). The G57R mutation initiated expansion of the DH270 
bnAb lineage. The low probability of this heterologous neutralization-conferring mutation 
and the complex lineage interactions that occurred is one explanation for why it took 4.5 
years for the DH270 lineage to expand.
The CH848 viral population underwent a transition from a long V1 loop in the TF (34 
residues) to short loops (16 to 17 residues) when escaping DH272/DH475 and facilitating 
expansion of DH270, to restoration of longer V1 loops later in infection as resistance to 
DH270 intermediates developed. Later DH270 antibodies adapted to viruses with longer V1 
loops, allowing recognition of a broader spectrum of Envs and enhancing breadth. DH270.6 
could neutralize heterologous viruses regardless of V1 loop length, but viruses with long 
loops tended to be less sensitive to it. Association of long V1 loops with reduced sensitivity 
was evident for three other V3-glycan bnAbs isolated from other individuals and may be a 
general feature of this class.
The V1 loop deletions in CH848 autologous virus removed the PNG site at position 137. 
Although the hypervariable nature of the V1 loop (which evolves by insertion and deletion, 
resulting in extreme length heterogeneity, as well as extreme variation in the number of PNG 
sites) complicates the interpretation of direct comparisons among unrelated HIV-1 strains, it 
is worth noting that a PNG site in this region specified as N137 was shown to be important 
for regulating affinity maturation of the PGT121 V3-glycan bnAb family, with some 
members of the lineage (PGT121 to PGT123) evolving to bind and others (PGT124) to 
accommodate or avoid this glycan (29).
Because we cannot foresee the susceptibility of each specific potential TF virus to a 
particular bnAb lineage it will be important for a vaccine to induce bnAbs against multiple 
epitopes on the HIV-1 Env to minimize TF virus escape (30, 31). In particular, induction of 
bnAb specificities beyond the HIV-1 V3-glycan epitope is critical for use in Asian 
populations where CRF01 strains (which, for the most part, lack the N332 PNG site required 
for efficient neutralization by V3-glycan bnAbs) are frequently observed.
Regarding what might have stimulated the UCA of the DH270 bnAb lineage the absence of 
detectable binding to the CH848 TF Env raised at least two possibilities. One is that the 
lineage arose at the end of year 1, either from a primary response to viruses present at that 
time (for example, with deletions in V1–V2) or from a subversion of an antibody lineage 
initially elicited by some other antigens. The other is that some altered form of the CH848 
TF Env protein (for example, shed gp120, or a fragment of it) exposed the V3 loop and the 
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N301 and N332 glycans in a way that bound and stimulated the germline B cell receptor 
(BCR), although the native CH848 TF Env did not. Our findings suggest that a denatured, 
fragmented, or otherwise modified form of Env may have initiated the DH270 lineage. We 
cannot exclude that the DH270.UCA could not bind to autologous Env as an IgG but could 
potentially be triggered as an IgM BCR on a cell surface.
It will be important to define how often an improbable mutation such as G57R determines 
the time it takes for a bnAb lineage in an HIV-1–infected individual to develop and how 
many of the accompanying mutations are necessary for potency or breadth, rather than being 
nonessential mutations at AID mutational hotspots (11, 32). Mutations of the latter type 
might condition the outcome or modulate the impact of a key, improbable mutation, without 
contributing directly to affinity. Should the occurrence of an unlikely mutation be rate-
limiting for breadth or potency in many other cases, a program of rational immunogen 
design will need to focus on modified Envs most likely to select very strongly for 
improbable yet critical antibody nucleotide changes.
The following proposal for a strategy for inducing V3-glycan bnAbs recreates the events that 
led to bnAb induction in CH848: starting by priming with a ligand that binds the bnAb 
UCA, such as the synthetic glycopeptide mimic of the V3-glycan bnAb gp120 epitope, and 
then boosting with an Env that can select G57R CDR H2 mutants, followed by Envs with 
progressive V1 lengths (fig. S22). We hypothesize that more direct targeting of V3-glycan 
UCAs and intermediate antibodies can accelerate the time of V3-glycan bnAb development 
in the setting of vaccination.
A limitation of this approach is that the selection of immunogens was based on the analysis 
of a single lineage from a single individual, and how frequently DH270-like lineages are 
present in the general population is unknown. Finally, our study describes a general strategy 
for the design of vaccine immunogens that can select specific antibody mutations, thereby 
directing antibody lineage maturation pathways.
MATERIAL AND METHODS
Study design
The CH848 donor, from which the DH270, DH272, and DH475 antibody lineages were 
isolated, is an African male enrolled in the CHAVI (Center for HIV/AIDS Vaccine 
Immunology) 001 acute HIV-1 infection cohort (33) and followed for 5 years, after which he 
started antiretroviral therapy. During this time, viral load ranged from 8927 to 442,749 
copies/ml (median, 61,064 copies/ml), and CD4 counts ranged from 288 to 624 cells/mm3 
(median, 350 cells/mm3). The time of infection was estimated by analyzing the sequence 
diversity in the first available sample using the Poisson-Fitter tool, as described in (10). 
Results were consistent with a single founder virus establishing the infection (34).
The mAbs DH270.1 and DH270.3 were isolated from cultured memory B cells isolated 205 
weeks after transmission (14). The mAbs DH270.6 and DH475 were isolated from Man9-V3 
glycopeptide–specific memory B cells collected 232 and 234 weeks after transmission, 
respectively, using direct sorting. The mAbs DH270.2, DH270.4, and DH270.5 were 
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isolated from memory B cells collected 232 weeks after transmission that bound to 
Consensus C gp120 Env but not to Consensus C N332A gp120 Env, using direct sorting.
Experimental methods
Detailed description of experimental methods is provided in Supplementary Materials and 
Methods.
Statistical analyses
Statistical analysis was performed using R. The specific tests used to determine significance 
are reported for each instance in the text.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. DH270 lineage with time of appearance and neutralization by selected members
(A) Phylogenetic relationship of six monoclonal antibodies (mAbs) and 93 NGS VH(D)JH 
sequence reads in the DH270 clonal lineage. External nodes (filled circles) represent 
VH(D)JH nucleotide sequences of either antibodies retrieved from cultured and sorted 
memory B cells (labeled) or a curated data set of NGS VH(D)JH rearrangement reads 
(unlabeled). Coloring is by time of isolation. Samples from weeks 11, 19, 64, 111, 160, 186, 
and 240 were tested, and time points from which no NGS reads within the lineage were 
retrieved are reported in table S2. Internal nodes (open circles) represent inferred ancestral 
intermediate sequences. Units for branch-length estimates are nucleotide substitution per 
site. (B) Neutralization dendrograms display single mAb neutralization of a genetically 
diverse panel of 207 HIV-1 isolates. Coloring is by median inhibitory concentration (IC50). 
See also data set S1.
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Fig. 2. Heterologous breadth in the DH270 lineage
(A) Neutralizing activity of DH270.1, DH270.5, and DH270.6 bnAbs (columns) for 207 tier 
2 heterologous viruses (rows). Coloring is by neutralization IC50 (in μg/ml). The first 
column displays the presence of a PNG site at position 332 (blue), at N334 (orange), or at 
neither one (black). The second column indicates the clade of each individual HIV-1 strain 
and is color-coded as indicated: clade A, green; clade B, blue; clade C, yellow; clade D, 
purple; CRF01, pink; clade G, cyan; others, gray. See data set S1. (B). Heterologous 
neutralization of all DH270 lineage antibodies for a 24-virus panel. Color coding for the 
presence of PNG sites, clade, and IC50 is the same as in (A). See fig. S1 and data set S3. (C) 
Covariation between VH mutation frequencies (x axis), neutralization breadth (y axis, top), 
and potency (y axis, bottom) of individual antibodies against viruses with a PNG site at 
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position N332 from the larger (left) and smaller (right) pseudovirus panels. (D) Correlation 
between viral V1 loop length and DH270 lineage antibody neutralization. Top: 
Neutralization of 17 viruses (with N332; sensitive to at least one DH270 lineage antibody) 
by selected DH270 lineage antibodies from unmutated common ancestor (UCA) to mature 
bnAbs (x axis). Viruses are identified by their respective V1 loop lengths (y axis); for each 
virus, neutralization sensitivity is indicated by an open circle, and resistance is indicated by a 
solid circle. The P value is a Wilcoxon rank sum comparison of V1 length distributions 
between sensitive and resistant viruses. Bottom: Regression lines (IC50 for neutralization 
versus V1 loop length) for DH270.1 and DH270.6, with a P value based on Kendall’s τ.
Bonsignori et al. Page 19
Sci Transl Med. Author manuscript; available in PMC 2017 August 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. A single disfavored mutation early during DH270 clonal development conferred 
neutralizing activity on the V3-glycan bnAb DH270 precursor antibodies
(A) Nucleotide alignment of DH270.IA4 and DH272 to VH1–2*02 sequence at the four VH 
positions that mutated from DH270.UCA to DH270.IA4. The mutated codons are 
highlighted in yellow. AID hotspots are indicated by red lines (solid, canonical; dashed, 
noncanonical); AID cold spots are indicated by blue lines (solid, canonical; dashed, 
noncanonical) (20). At position 169, DH270.IA4 retained positional conformity with DH272 
but not identity conformity (red boxes). (B) Sequence logo plot of amino acids mutated from 
germline (top) in the NGS reads of the DH270 (middle) and DH272 (bottom) lineages at 
weeks 186 and 111 after transmission, respectively. Red asterisks indicate amino acids 
mutated in DH270.IA4. The black arrow indicates lack of identity conformity between the 
two lineages at amino acid position 57. (C) Sequence logo plot of nucleotide mutations 
(positions 165 to 173) in the DH270 and DH272 lineages at weeks 186 and 111 after 
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transmission, respectively. The arrow indicates position 169. (D) Effect of reversion 
mutations on DH270.IA4 neutralization. Coloring is by IC50. WT, wild type. (E) Effect of 
G57R mutation on DH270.UCA auto-logous (top) and heterologous (bottom) neutralizing 
activity.
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Fig. 4. Cooperation among DH270, DH272, and DH475 N332-dependent V3-glycan neutralizing 
antibody lineages
(A) Neutralizing activity of DH272, DH475, and DH270 lineage antibodies (columns) 
against 90 autologous viruses isolated from CH848 over time (rows). Neutralization potency 
(IC50) is shown as indicated in the bar. For each pseudovirus, presence of a PNG site at 
N332 or N334, and V1 loop length are indicated in the right columns. See also data set S2. 
(B and C) Susceptibility of autologous viruses bearing selected immunotype-specific 
mutations to DH270.1 and to DH475 (B) or DH272 (C).
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Fig. 5. Fab/scFv crystal structures and three-dimensional reconstruction of DH270.1 bound with 
the 92BR SOSIP.664 trimer
Superposition of backbone ribbon diagrams for the DH270 lineage members: UCA1 (gray), 
DH270.1 (green), and DH270.6(blue)alone(A), withtheDH272cooperating antibody (red) 
(B), with PGT128 (magenta) (C), and with PGT124 (orange) (D). Arrows indicate major 
differences in CDR regions. Top (E) and side (F) views of a fit of the DH270.1 Fab (green) 
and the BG505 SOSIP trimer (gray) onto a map obtained from negative-stain EM. Top (G) 
and side (H) views of the BG505 trimer [Protein Data Bank (PDB) ID: 5ACO] (28) (gray, 
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with V1-V2 and V3 loops highlighted in red and blue, respectively) bound to PGT124 (PDB 
ID: 4R2G) (27) (orange), PGT128 (PDB ID: 3TYG) (17) (magenta), PGT135 (PDB ID: 
4JM2) (22) (cyan), and DH270.1 (green), superposed. The arrows indicate the direction of 
the principal axis of each of the bnAb Fabs; the color of each arrow matches that of the 
corresponding bnAb. See also fig. S18.
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Fig. 6. DH270 lineage antibody binding to autologous CH848 Env components
(A) Binding of DH270 lineage antibodies (column) to 120 CH848 autologous gp120 Env 
glycoproteins (rows) grouped on the basis of time of isolation (w, week; d, day; black and 
white blocks). The last three rows show the neutralization profile of the three autologous 
viruses that lost the PNG at position N332 (blue blocks). V1 amino acid length of each virus 
is color-coded as indicated. Antibody binding is measured by enzyme-linked 
immunosorbent assay, expressed as log area under the curve (LogAUC), and color-coded on 
the basis of the categories shown in the histogram. The histogram shows the distribution of 
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the measured values in each category. The black arrow indicated Env 10.17. Viruses isolated 
at and after week 186, which is the time of first evidence of DH270 lineage presence, are 
highlighted in different colors according to week of isolation. (B) Left: Binding to CH848 
TF mutants with disrupted N301 and/or N332 glycan sites. Results are expressed as 
LogAUC. VH mutation frequency is shown in parentheses for each antibody (see also fig. 
S1A). Middle: Binding to CH848 Env trimer expressed on the cell surface of Chinese 
hamster ovary cells. Results are expressed as maximum percentage of binding and are 
representative of duplicate experiments. DH270 antibodies are in red. Palivizumab is the 
negative control (gray area). The curves indicate binding to the surface antigen on a scale of 
0 to 100 (y axis); the highest peak between the test antibody and the negative control sets the 
value of 100. Right: Binding to free glycans measured on a microarray. Results are the 
average of background-subtracted triplicate measurements and are expressed in relative units 
(RU).
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